New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19

This Medical News story discusses new guidelines for the use of pemivibart, a monoclonal antibody marketed as Pemgarda, as preexposure prophylaxis against COVID-19 in immunocompromised individuals.

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2024-10, Vol.332 (14), p.1127-1129
Main Author: Bock, Anna
Format: Article
Language:English
Subjects:
COVID-19
Immune system
Immunocompromised hosts
Infectious diseases
Leukemia
Lymphoma
Severe acute respiratory syndrome coronavirus 2
Stem cell transplantation
Stem cells
Viral diseases
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This Medical News story discusses new guidelines for the use of pemivibart, a monoclonal antibody marketed as Pemgarda, as preexposure prophylaxis against COVID-19 in immunocompromised individuals.
ISSN:0098-7484
1538-3598
1538-3598
DOI:10.1001/jama.2024.18589